Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Clinical Significance of Stanniocalcin2 mRNA Expression in Patients With Colorectal Cancer

TAKUO WATANABE, MANABU SHIOZAWA, YAYOI KIMURA, YUKIHIKO HIROSHIMA, ITARU HASHIMOTO, KEISUKE KOMORI, HAYATO WATANABE, KAZUKI KANO, HIROHITO FUJIKAWA, TORU AOYAMA, MASAKATSU NUMATA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, TAKASHI OGATA, NORIO YUKAWA, SOICHIRO MORINAGA, YASUSHI RINO, MUNETAKA MASUDA, YOHEI MIYAGI and TAKASHI OSHIMA
Anticancer Research April 2021, 41 (4) 2117-2122; DOI: https://doi.org/10.21873/anticanres.14983
TAKUO WATANABE
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANABU SHIOZAWA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YAYOI KIMURA
3Advanced Medical Research Centre, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIHIKO HIROSHIMA
4Kanagawa Cancer Centre Research Institute, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ITARU HASHIMOTO
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEISUKE KOMORI
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HAYATO WATANABE
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUKI KANO
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROHITO FUJIKAWA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORU AOYAMA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAKATSU NUMATA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKANOBU YAMADA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI TAMAGAWA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI OGATA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO YUKAWA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOICHIRO MORINAGA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI RINO
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MUNETAKA MASUDA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOHEI MIYAGI
4Kanagawa Cancer Centre Research Institute, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI OSHIMA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: oshimat@kcch.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Stanniocalcin2 (STC2) is associated with proliferation, invasion, and metastasis in various cancers. We examined the clinical significance of STC2 mRNA expression in patients with colorectal cancer (CRC). Patients and Methods: Relative expression levels of STC2 mRNA in CRC tissues and corresponding normal mucosa obtained from 202 patients were measured using quantitative real-time reverse transcriptase-polymerase chain reaction. Results: Expression of STC2 mRNA was higher in the cancer tissue than in the adjacent normal mucosa. STC2 mRNA expression in cancer tissues was associated with tumour size, liver metastasis, venous invasion, and lymph node metastasis. High expression of STC2 mRNA was significantly associated with poorer postoperative survival (p=0.0003). Multivariate analysis showed that high expression of STC2 mRNA was an independent predictor of postoperative survival. Conclusion: High expression of STC2 mRNA in CRC tissue may be a useful prognostic marker in patients with CRC.

Key Words:
  • Stanniocalcin2
  • colorectal cancer
  • prognostic factor

The number of new cases of colorectal cancer (CRC) worldwide in 2020 was 1,931,590, accounting for 10.0% of all cancers, the third highest, and the number of deaths from CRC in 2020 was 915,880, accounting for 9.2% of all cancers, the second-highest (1).

Most CRC cases are not hereditary but sporadic. This is due to genetic instability and multiple somatic mutations. About 80% of CRC cases are diagnosed at stage I and are curable. Surgery is the primary treatment for localised advanced (stage II/III) CRC. In patients with stage III CRC, the standard treatment is curative resection and postoperative chemotherapy (2). Multimodality therapy in combination with surgery, cytotoxic chemotherapy, and molecular targeted agents prolong the survival of advanced CRC. However, only a small number of patients with highly advanced CRC can be cured using these treatments. Thus, it is very important to identify new targets and personalise therapy based on biomarkers (3-5).

The STC family consists of two members, STC1 and STC2, which are secreted glycoproteins that regulate homeostasis of phosphate and calcium (6). We previously reported the clinical significance of expression of STC1 mRNA in patients with CRC (7).

STC2 is expressed in various normal tissues, including the pancreas, spleen, kidney, and skeletal muscle, and is involved in cellular calcium/phosphate regulation and cell metabolism (8, 9). In addition, STC2 is involved in human carcinogenesis (10, 11). STC2 is also reportedly associated with tumour invasion and metastasis in various cancers (12-15).

In the present study, we measured expression of STC2 mRNA in CRC tissues and corresponding normal mucosa and examined the association between expression of mRNA and clinicopathological characteristics and postoperative survival to clarify the clinical significance of expression of STC2 mRNA in cancer tissues in patients with CRC.

Patients and Methods

Patients and samples. This study was approved by the Ethics Committees of Yokohama City Medical Centre (approval number: 18-7A-4) and Kanagawa Cancer Centre (approval number: epidemiological study-29). We used cancer tissues and corresponding normal mucosa from surgery samples of 202 patients with CRC who underwent surgery at the Kanagawa Cancer Centre and Yokohama City University Medical Centre between 2003 and 2006. Each tissue sample was immediately embedded in Optimum Cutting Temperature compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan) after resection and was immediately frozen in liquid nitrogen and stored in an ultra-low temperature freezer at –80°C. Each specimen was stained with hematoxylin and eosin for histopathological evaluation. Samples containing more than 80% of cancer cells were used as GC tissue for the preparation of total RNA extracts.

RNA extraction and complementary DNA (cDNA) synthesis. Total RNA was extracted from the CRC tissue and adjacent normal mucosa using TRIzol Reagent (GIbco, Life Technologies, Gaitherburg, MD, USA). cDNA was synthesised from 400 ng of total RNA using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). After synthesis of cDNA, the cDNA was diluted to 20% with pure water and stored in an ultra-low temperature freezer at –80°C.

Real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). qRT-PCR was carried out using iQSYBR-Green Supermix (Bio-Rad Laboratories). PCR reactions were performed in a total volume of 30 μl, containing cDNA derived from 150 μg of RNA, 54 nM of each primer, 15 μl of iQSYBR-Green Supermix containing 100 U/ml of iTag DNA polymerase and 800 μM of dNTPs. Expression of β-actin mRNA was used as an internal control. PCR protocol was performed as follows: first 3 min at 95°C; 40 cycles of cDNA denaturation for 15 s at 95°C, annealing for 15 s at 56°C for STC2 mRNA and 60°C for β-actin mRNA, and a primer extension for 30 s at 72°C; last, 10 min at 72°C. PCR primer sequences of STC2 and β-actin are shown in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

PCR primers and conditions.

Statistical analysis. Expression levels of STC2 mRNA in cancer tissues and corresponding normal mucosa were compared using the Wilcoxon test. Expression levels of STC2 mRNA were categorised as low or high (low expression group: n=101, high expression group: n=101) according to the median expression level of STC2 mRNA in tumour tissues. Associations between relative expression of STC2 mRNA and explanatory variables, including age, sex, tumour size, depth of invasion, tumour location, lymph node metastasis, liver metastasis, TMN stage, venous invasion, lymphatic invasion, and histological type, were analysed using the χ2 test. The association between expression of STC2 mRNA and postoperative survival was esteemed using the Kaplan–Meier method, and differences in survival rates were analysed using the log-rank test. Univariate and multivariate analyses using A Cox proportional-hazards regression model were performed to determine the predictive postoperative survivals. All statistical analyses were performed using IBM SPSS Statistics 20 (SPSS, Inc., Chicago, IL, USA). Two-tailed p-values were calculated, and a difference was considered significant when p-value was less than 0.05.

Results

STC2 mRNA expression in CRC tissue and corresponding normal mucosa. Expression of STC2 mRNA in CRC tissues was significantly higher than that in corresponding normal mucosa (p=0.0012 via Wilcoxon test; Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Expression of STC2 mRNA in CRC tissues and adjacent normal mucosa. Expression of STC2 mRNA in CRC tissues was significantly higher than those in adjacent normal mucosa (p=0.0012 via Wilcoxon test).

Relationship between STC2 mRNA expression level and clinicopathological features. Expression levels of STC2 mRNA were categorised as low expression group (n=101) and high expression group (n=101) according to the median expression level of STC2 mRNA in cancer tissues. High expression of STC2 was significantly associated with tumour size >65 mm in diameter, presence of lymph node metastases, presence of venous invasion, and presence of liver metastases (Table II).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Association between the expression of STC2 mRNA and clinicopathological characteristics.

Relationship between STC2 mRNA expression level in CRC tissues and outcomes in patients with CRC. Postoperative survival in patients with high expression levels of STC2 mRNA in CRC tissues was significantly poorer than that in those with low expression levels of STC2 mRNA expression levels (p=0.0003; Figure 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Relationships between the expression of STC2 and outcomes in patients with CRC. Postoperative survival in patients with high expression of STC2 expression in cancer tissue was significantly poorer than that in patients with low expression of STC2 mRNA (59.1% vs. 88.8%; p=0.0003 via the log-rank test).

Univariate and multivariate analyses of clinicopathological characteristics and expression of STC2 mRNA. Univariate analysis using Cox proportional-hazards model revealed that tumour size, histological type, depth of invasion, lymph node metastasis, lymphatic invasion, liver metastasis, and expression of STC2 mRNA levels were significantly associated with the outcomes of patients with CRC. Multivariate Cox proportional-hazards regression analysis showed that STC2 mRNA expression, as well as depth of tumour, lymph node metastasis, and liver metastasis, were independently related to postoperative survival (p=0.016, 0.018, 0.011, >0.001, respectively; Table III).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate and multivariate analysis of clinicopathological characteristics and STC2 mRNA expression for OS.

Discussion

In this study, to evaluate the clinical significance of STC2 mRNA expression in patients with CRC, we measured expression of mRNA in cancer tissues and corresponding normal mucosa specimens from patients and analysed the association of the expression of STC2 mRNA with clinicopathological characteristics and postoperative survivals.

First, we compared expression of STC2 mRNA in CRC tissues and corresponding normal mucosa from 202 cases. A previous study reported that expression of STC2 mRNA expression in cancer tissue in 63 patients with oesophageal cancer was higher than that in the corresponding normal mucosa (p<0.001) (12). Wang et al. compared expression of STC2 mRNA in cancer tissue and corresponding normal mucosal from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). They reported that expression levels of STC2 mRNA in cancer tissues were higher compared with those in corresponding normal tissues in patients with CRC in the TCGA database (n=383), and the same results were obtained from all eight gene expression profiles downloaded from the GEO database gene expression analyses identifying a relationship between STC 2 and the malignant behaviour of CRC (16). In the present study, expression of STC2 mRNA in CRC tissues was significantly higher than that in the corresponding normal mucosa (p<0.001).

Next, we studied the relationship between expression of STC2 mRNA and clinicopathological characteristics. A previous study reported that expression of STC2 mRNA in CRC tissue was associated with lymph node metastasis, distant metastasis including liver metastasis, and clinical stage (17). Wang et al. reported the association between STC2 mRNA expression and the clinicopathological features in patients with CRC from the TCGA dataset (n=383). They reported that expression of STC2 mRNA in cancer tissues was associated with the position (colon vs. rectum), side (left vs. right), depth (T1+T2 vs. T3+T4), lymph node metastasis, and AJCC stage (I+II vs. III+IV) (16). In our study, expression of STC2 mRNA in CRC tissues was significantly associated with tumour size, lymph node metastasis, venous invasion, and liver metastasis.

Next, we examined the relationship between expression of STC2 mRNA in cancer tissues and postoperative survival. It was reported that STC2 over-expression is correlated with poor prognosis in patients with nasopharyngeal carcinomas (18). Zhang et al. reported that the positive expression of STC2 correlates with poor overall survival (OS) and disease-free survival in patients with hepatocellular carcinoma (19). It was reported that patients with pancreatic cancer with high STC2 expression have a lower 5-year OS rate than patients with low STC2 expression (20). In the present study, the 5-year OS was significantly poorer in the high expression of STC2 mRNA group than that in the low expression of STC2 group.

Furthermore, we performed univariate and multivariate analyses of clinicopathological characteristics and STC2 mRNA expression to identify independent predictive factors for postoperative survival in patients with CRC. In a previous TCGA database analysis (n=383), it was reported that STC2 expression levels in CRC tissues and distant metastasis were independent predictive factors for postoperative survival [Hazard ratio (HR)=2.338, 95% confidence interval (CI)=1.189-4.599, p=0.014] (14). It was also reported, using multivariate Cox regression analysis, that OS of 115 CRC patients, distant metastasis, and STC2 expression (HR=1.976, 95%CI=1.092–3.576, p=0.024) were independent prognostic factors for CRC. Here, similar to the above, univariate Cox regression analysis showed that tumour size, histological type, depth of invasion, lymph node metastasis, lymphatic invasion, liver metastasis, and STC2 mRNA expression in cancer tissues were significant predictive factors for OS. Multivariate Cox regression analyses also showed that lymph node metastasis, depth of invasion, liver metastasis, and expression of STC2 mRNA (HR=1.72, 95%CI=1.011-3.027, p=0.016) were independent predictive factors of postoperative survival.

Elucidation of the mechanism of relationship between high STC2 expression and poor outcomes in patients with CRC remains insufficient. Three mechanisms were considered from previous reports. The first is the increase in cell proliferation, migration, and invasion by STC2. In a study using head and neck squamous cell carcinoma cells, Yang et al. reported that STC2 may induce the invasion of cancer cells and exert a strong growth permissive effect on cancer cells (21). The second is the anti-apoptotic effect of STC2. Cells expressing STC2 are reportedly resistant to apoptosis (22) through the inhibition of plasma membrane store-operated Ca2+ entry (23). The anti-apoptosis effect of STC2 was shown in cells under hypoxic stress, processes that have profound consequences for tumour growth. Moreover, the STC2 was shown to be a downstream target of HIF-1 and PERK-ATF4 (24-26). The third is the promotion of the epithelial-mesenchymal transition (EMT) by STC2. Chen et al. reported that STC2 promotes CRC tumorigenesis and EMT progression by activating ERK/MEK and PI3K/AKT signalling pathways (27).

Our study has several limitations. First, we only examined the expression of STC2 mRNA in cancer tissues and corresponding normal mucosa obtained from patients with CRC. Although we think that there is a strong association between the expression of STC2 mRNA and that of protein, we should have performed immunohistochemical studies using the same specimens. Second, we must be conscious of the existence of heterogeneity in the CRC specimens, which might pose a challenge. mRNA extraction was performed using 5-mm square CRC tissue specimens. Although these specimens were collected from the vicinity of the most advanced part of the cancer tissue, they might not faithfully represent the entire tumour.

In conclusion, our study is representative of CRC pathogenesis and high expression of STC2 mRNA in the cancer tissue may be a useful prognostic marker in patients with CRC.

Footnotes

  • Authors’ Contributions

    TW and TO designed the study, participated in the analyses, and drafted the manuscript. All other Authors made substantial contributions to data collection, analysis, and interpretation, as well as to the editing and approval of the final manuscript.

  • Conflicts of Interest

    The Authors declare that there are no conflicts of interest in relation to this study.

  • Received February 11, 2021.
  • Revision received February 20, 2021.
  • Accepted February 22, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. International Agency for Research on Cancer
    : Global Cancer observatory. Available at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf [Last accessed on February 21, 2021]
  2. ↵
    1. Van Cutsem E,
    2. Cervantes A,
    3. Adam R,
    4. Sobrero A,
    5. Van Krieken JH,
    6. Aderka D,
    7. Aranda Aguilar E,
    8. Bardelli A,
    9. Benson A,
    10. Bodoky G,
    11. Ciardiello F,
    12. D’Hoore A,
    13. Diaz-Rubio E,
    14. Douillard JY,
    15. Ducreux M,
    16. Falcone A,
    17. Grothey A,
    18. Gruenberger T,
    19. Haustermans K,
    20. Heinemann V,
    21. Hoff P,
    22. Köhne CH,
    23. Labianca R,
    24. Laurent-Puig P,
    25. Ma B,
    26. Maughan T,
    27. Muro K,
    28. Normanno N,
    29. Österlund P,
    30. Oyen WJ,
    31. Papamichael D,
    32. Pentheroudakis G,
    33. Pfeiffer P,
    34. Price TJ,
    35. Punt C,
    36. Ricke J,
    37. Roth A,
    38. Salazar R,
    39. Scheithauer W,
    40. Schmoll HJ,
    41. Tabernero J,
    42. Taïeb J,
    43. Tejpar S,
    44. Wasan H,
    45. Yoshino T,
    46. Zaanan A and
    47. Arnold D
    : ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8): 1386-1422, 2016. PMID: 27380959. DOI: 10.1093/annonc/mdw235
    OpenUrlCrossRefPubMed
  3. ↵
    1. Scheipner L,
    2. Smolle MA,
    3. Barth D,
    4. Posch F,
    5. Stotz M,
    6. Pichler M,
    7. StÖger H,
    8. Gerger A and
    9. Riedl JM
    : The AST/ALT ratio is an independent prognostic marker for disease-free survival in stage II and III colorectal carcinoma. Anticancer Res 41(1): 429-436, 2021. PMID: 33419840. DOI: 10.21873/anticanres.14792
    OpenUrlAbstract/FREE Full Text
    1. Huang RH,
    2. Yang WK,
    3. Wu CM,
    4. Yeh CM and
    5. Sung WW
    : Over-expression of CEP55 predicts favorable prognosis in colorectal cancer patients with lymph node involvement. Anticancer Res 41(1): 543-547, 2021. PMID: 33419854. DOI: 10.21873/anticanres.14806
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Vycital O,
    2. Pitule P,
    3. Hosek P,
    4. Kriz T,
    5. Treska V and
    6. Liska V
    : Expression of Serpin B9 as a prognostic factor of colorectal cancer. Anticancer Res 39(11): 6063-6066, 2019. PMID: 31704833. DOI: 10.21873/anticanres.13813
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Chang AC and
    2. Reddel RR
    : Identification of a second stanniocalcin cDNA in mouse and human: Stanniocalcin 2. Mol Cell Endocrinol 141(1-2): 95-99, 1998. PMID: 9723890. DOI: 10.1016/s0303-7207(98)00097-5
    OpenUrlCrossRefPubMed
  6. ↵
    1. Tamura S,
    2. Oshima T,
    3. Yoshihara K,
    4. Kanazawa A,
    5. Yamada T,
    6. Inagaki D,
    7. Sato T,
    8. Yamamoto N,
    9. Shiozawa M,
    10. Morinaga S,
    11. Akaike M,
    12. Kunisaki C,
    13. Tanaka K,
    14. Masuda M and
    15. Imada T
    : Clinical significance of STC1 gene expression in patients with colorectal cancer. Anticancer Res 31(1): 325-329, 2011. PMID: 21273618
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ishibashi K and
    2. Imai M
    : Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am J Physiol Renal Physiol 282(3): F367-F375, 2002. PMID: 11832417. DOI: 10.1152/ajprenal.00364.2000
    OpenUrlCrossRefPubMed
  8. ↵
    1. Olsen HS,
    2. Cepeda MA,
    3. Zhang QQ,
    4. Rosen CA,
    5. Vozzolo BL and
    6. Wagner GF
    : Human stanniocalcin: A possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA 93(5): 1792-1796, 1996. PMID: 8700837. DOI: 10.1073/pnas.93.5.1792
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Law AY and
    2. Wong CK
    : Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 316(3): 466-476, 2010. PMID: 19786016. DOI: 10.1016/j.yexcr.2009.09.018
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gagliardi AD,
    2. Kuo EY,
    3. Raulic S,
    4. Wagner GF and
    5. DiMattia GE
    : Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs. Am J Physiol Endocrinol Metab 288(1): E92-105, 2005. PMID: 15367391. DOI: 10.1152/ajpendo.00268.2004
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kita Y,
    2. Mimori K,
    3. Iwatsuki M,
    4. Yokobori T,
    5. Ieta K,
    6. Tanaka F,
    7. Ishii H,
    8. Okumura H,
    9. Natsugoe S and
    10. Mori M
    : STC2: A predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Ann Surg Oncol 18(1): 261-272, 2011. PMID: 20734150. DOI: 10.1245/s10434-010-1271-1
    OpenUrlCrossRefPubMed
    1. Yokobori T,
    2. Mimori K,
    3. Ishii H,
    4. Iwatsuki M,
    5. Tanaka F,
    6. Kamohara Y,
    7. Ieta K,
    8. Kita Y,
    9. Doki Y,
    10. Kuwano H and
    11. Mori M
    : Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol 17(10): 2601-2607, 2010. PMID: 20422456. DOI: 10.1245/s10434-010-1086-0
    OpenUrlCrossRefPubMed
  12. ↵
    1. Buckanovich RJ,
    2. Sasaroli D,
    3. O’Brien-Jenkins A,
    4. Botbyl J,
    5. Hammond R,
    6. Katsaros D,
    7. Sandaltzopoulos R,
    8. Liotta LA,
    9. Gimotty PA and
    10. Coukos G
    : Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25(7): 852-861, 2007. PMID: 17327606. DOI: 10.1200/JCO.2006.08.8583
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Meyer HA,
    2. Tölle A,
    3. Jung M,
    4. Fritzsche FR,
    5. Haendler B,
    6. Kristiansen I,
    7. Gaspert A,
    8. Johannsen M,
    9. Jung K and
    10. Kristiansen G
    : Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol 55(3): 669-678, 2009. PMID: 18450365. DOI: 10.1016/j.eururo.2008.04.001
    OpenUrlCrossRefPubMed
  14. ↵
    1. Wang J,
    2. Sahengbieke S,
    3. Xu X,
    4. Zhang L,
    5. Xu X,
    6. Sun L,
    7. Deng Q,
    8. Wang D,
    9. Chen D,
    10. Pan Y,
    11. Liu Z and
    12. Yu S
    : Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer. Onco Targets Ther 11: 7155-7168, 2018. PMID: 30425508. DOI: 10.2147/OTT.S167780
    OpenUrlCrossRefPubMed
  15. ↵
    1. Zhang C,
    2. Chen S,
    3. Ma X,
    4. Yang Q,
    5. Su F,
    6. Shu X,
    7. Xie W,
    8. Feng M and
    9. Xiong B
    : Upregulation of STC2 in colorectal cancer and its clinicopathological significance. Onco Targets Ther 12: 1249-1258, 2019. PMID: 30863092. DOI: 10.2147/OTT.S191609
    OpenUrlCrossRefPubMed
  16. ↵
    1. Lin S,
    2. Guo Q,
    3. Wen J,
    4. Li C,
    5. Lin J,
    6. Cui X,
    7. Sang N and
    8. Pan J
    : Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res 33: 26, 2014. PMID: 24606961. DOI: 10.1186/1756-9966-33-26
    OpenUrlCrossRefPubMed
  17. ↵
    1. Zhang ZH,
    2. Wu YG,
    3. Qin CK,
    4. Rong ZH,
    5. Su ZX and
    6. Xian GZ
    : Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma. Oncol Lett 8(5): 2160-2164, 2014. PMID: 25289096. DOI: 10.3892/ol.2014.2520
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lin C,
    2. Sun L,
    3. Huang S,
    4. Weng X and
    5. Wu Z
    : stc2 is a potential prognostic biomarker for pancreatic cancer and promotes migration and invasion by inducing epithelial-mesenchymal transition. Biomed Res Int 2019: 8042489, 2019. PMID: 32258098. DOI: 10.1155/2019/8042489
    OpenUrlCrossRef
  19. ↵
    1. Yang S,
    2. Ji Q,
    3. Chang B,
    4. Wang Y,
    5. Zhu Y,
    6. Li D,
    7. Huang C,
    8. Wang Y,
    9. Sun G,
    10. Zhang L,
    11. Guan Q,
    12. Xiang J,
    13. Wei W,
    14. Lu Z,
    15. Liao T,
    16. Meng J,
    17. Wang Z,
    18. Ma B,
    19. Zhou L,
    20. Wang Y and
    21. Yang G
    : STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget 8(4): 5976-5991, 2017. PMID: 27863406. DOI: 10.18632/oncotarget.13355
    OpenUrlCrossRefPubMed
  20. ↵
    1. Chang AC,
    2. Jellinek DA and
    3. Reddel RR
    : Mammalian stanniocalcins and cancer. Endocr Relat Cancer 10(3): 359-373, 2003. PMID: 14503913. DOI: 10.1677/erc.0.0100359
    OpenUrlAbstract
  21. ↵
    1. Zeiger W,
    2. Ito D,
    3. Swetlik C,
    4. Oh-hora M,
    5. Villereal ML and
    6. Thinakaran G
    : Stanniocalcin 2 is a negative modulator of store-operated calcium entry. Mol Cell Biol 31(18): 3710-3722, 2011. PMID: 21746875. DOI: 10.1128/MCB.05140-11
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Law AY and
    2. Wong CK
    : Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 316(3): 466-476, 2010. PMID: 19786016. DOI: 10.1016/j.yexcr.2009.09.018
    OpenUrlCrossRefPubMed
    1. Ito D,
    2. Walker JR,
    3. Thompson CS,
    4. Moroz I,
    5. Lin W,
    6. Veselits ML,
    7. Hakim AM,
    8. Fienberg AA and
    9. Thinakaran G
    : Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 24(21): 9456-9469, 2004. PMID: 15485913. DOI: 10.1128/MCB.24.21.9456-9469.2004
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Law AY,
    2. Lai KP,
    3. Ip CK,
    4. Wong AS,
    5. Wagner GF and
    6. Wong CK
    : Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res 314(8): 1823-1830, 2008. PMID: 18394600. DOI: 10.1016/j.yexcr.2008.03.001
    OpenUrlCrossRefPubMed
  24. ↵
    1. Chen B,
    2. Zeng X,
    3. He Y,
    4. Wang X,
    5. Liang Z,
    6. Liu J,
    7. Zhang P,
    8. Zhu H,
    9. Xu N and
    10. Liang S
    : STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways. Oncotarget 7(44): 71400-71416, 2016. PMID: 27662663. DOI: 10.18632/oncotarget.12147
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (4)
Anticancer Research
Vol. 41, Issue 4
April 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Significance of Stanniocalcin2 mRNA Expression in Patients With Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Clinical Significance of Stanniocalcin2 mRNA Expression in Patients With Colorectal Cancer
TAKUO WATANABE, MANABU SHIOZAWA, YAYOI KIMURA, YUKIHIKO HIROSHIMA, ITARU HASHIMOTO, KEISUKE KOMORI, HAYATO WATANABE, KAZUKI KANO, HIROHITO FUJIKAWA, TORU AOYAMA, MASAKATSU NUMATA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, TAKASHI OGATA, NORIO YUKAWA, SOICHIRO MORINAGA, YASUSHI RINO, MUNETAKA MASUDA, YOHEI MIYAGI, TAKASHI OSHIMA
Anticancer Research Apr 2021, 41 (4) 2117-2122; DOI: 10.21873/anticanres.14983

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Clinical Significance of Stanniocalcin2 mRNA Expression in Patients With Colorectal Cancer
TAKUO WATANABE, MANABU SHIOZAWA, YAYOI KIMURA, YUKIHIKO HIROSHIMA, ITARU HASHIMOTO, KEISUKE KOMORI, HAYATO WATANABE, KAZUKI KANO, HIROHITO FUJIKAWA, TORU AOYAMA, MASAKATSU NUMATA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, TAKASHI OGATA, NORIO YUKAWA, SOICHIRO MORINAGA, YASUSHI RINO, MUNETAKA MASUDA, YOHEI MIYAGI, TAKASHI OSHIMA
Anticancer Research Apr 2021, 41 (4) 2117-2122; DOI: 10.21873/anticanres.14983
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI
  • Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety
  • Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • Stanniocalcin2
  • colorectal cancer
  • prognostic factor
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire